Toritz RA 500 mg Injection

Toritz RA 500 mg Injection contains rituximab 500 mg, a monoclonal antibody that targets CD20-positive B cells. It is used for certain blood cancers and autoimmune conditions such as rheumatoid arthritis under specific treatment protocols. The injection is administered as an intravenous infusion by a qualified healthcare professional.

BUY NOW

Rituximab binds to the CD20 antigen on B cells and helps the immune system eliminate these cells. Toritz RA is indicated in specific regimens for conditions including non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. The product is supplied as a 500 mg/50 mL solution in a single-dose vial and is manufactured by Torrent Pharmaceuticals Ltd. Treatment dosage and infusion schedule depend on the patient’s condition and the prescribed clinical protocol.

Technical Specification

Specification Details
Active Ingredient Rituximab
Strength 500 mg
Dosage Form Solution for Injection
Concentration 10 mg/mL
Volume 50 mL
Manufacturer Torrent Pharmaceuticals Ltd

Product Also Known As

Toritz RA 500 mg Injection, Toritz RA 500mg/50mL Injection, Rituximab 500 mg Injection, Rituximab 500 mg/50 mL Injection, Rituximab Infusion, Anti-CD20 Monoclonal Antibody, Rituximab Anticancer Injection